SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm
Kevin J. Hamblett(Seagen (United States)), William C. Fanslow(Laboratoire d'Innovation Thérapeutique), Robert R. Milburn(Amgen (United States)), Christopher J. Borths(Amgen (United States)), Kim Quon(Laboratoire d'Innovation Thérapeutique), Jesse L. Gurgel(Laboratoire d'Innovation Thérapeutique), Sonal Patel(Amgen (United States)), Dan A. Rock(Amgen (United States)), Mark Tometsko(Laboratoire d'Innovation Thérapeutique), Matthew M. Bio(Amgen (United States)), Sophia Siu(Amgen (United States)), Brooke M. Rock(Amgen (United States)), Wesley Chang(California Institute of Technology), Allison P. Jacob(Laboratoire d'Innovation Thérapeutique), Seamus P. Ragan(Seagen (United States)), Margaret F. Weidner(Laboratoire d'Innovation Thérapeutique), Jason O’Neill(Amgen (United States))
Cited by 135
Related Papers
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
|Clinical Cancer Research|2004|1.2k
Oxygen Reduction Electrocatalyst Based on Strongly Coupled Cobalt Oxide Nanocrystals and Carbon Nanotubes
|Journal of the American Chemical Society|2012|791
An ultrafast nickel–iron battery from strongly coupled inorganic nanoparticle/nanocarbon hybrid materials
|Nature Communications|2012|404
Quantitative Comparison of Long-wavelength Alexa Fluor Dyes to Cy Dyes: Fluorescence of the Dyes and Their Bioconjugates
|Journal of Histochemistry & Cytochemistry|2003|373
Reduction−Alkylation Strategies for the Modification of Specific Monoclonal Antibody Disulfides
|Bioconjugate Chemistry|2005|365